The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -5,522 | -5,940 | -5,131 | -22,816 |
| Stock-based compensation expense | 11 | 10 | 109 | 9,071 |
| Depreciation expense | 29 | -442 | 206 | 409 |
| Amortization of right-of-use assets | 191 | 648 | - | - |
| Prepaid expenses and other current assets | -254 | 408 | -126 | -501 |
| Accounts payable and accrued expenses | -661 | 997 | -1,490 | 147 |
| Operating lease liabilities | -172 | -154 | -145 | -278 |
| Net cash used in operating activities | -5,870 | -5,289 | -6,325 | -12,966 |
| Purchase of property and equipment | 2 | 104 | - | 0 |
| Net cash used in investing activities | -2 | -104 | - | 0 |
| Proceeds from the exercise of stock options | - | - | - | 0 |
| Sales of shares of common stock, net of costs | - | - | - | 0 |
| Payments on finance leases | 3 | 3 | 2 | 5 |
| Restricted stock units withheld to cover tax obligations | - | 0 | 207 | - |
| Net cash used in financing activities | -3 | -3 | -209 | -5 |
| Effect of foreign currency rates on cash | 11 | 6 | - | - |
| Net change in cash, cash equivalents, and restricted cash | - | - | -6,534 | -12,971 |
| Net change in cash, cash equivalents and restricted cash | -5,864 | -24,895 | - | - |
| Cash, cash equivalents and restricted cash at beginning of year | 48,333 | 53,723 | 73,228 | - |
| Cash, cash equivalents and restricted cash at end of period | 42,469 | 48,333 | 53,723 | - |
Actinium Pharmaceuticals, Inc. (ATNM)
Actinium Pharmaceuticals, Inc. (ATNM)